Sign in Subscribe
Drugs

AutoGenomics and Targeted Molecular Diagnostics Join Forces on Cancer Biomarkers

Strategic Insights

— 1 min read

AutoGenomics, Inc., and Targeted Molecular Diagnostics, Inc., have formed a 3-year development partnership to create novel cancer biomarkers for oncology. The collaboration will leverage the AutoGenomics INFINITI platform to develop tests for pharmaceutical and biotech companies, which will aid in the preclinical and clinical development of targeted therapies. The first assay will focus on the HER1 and HER2 pathways, providing valuable information for drug developers. Subsequent assays will cover breast cancer response, apoptotic response, and resistance to chemotherapy.

Key Takeaways:

  • The partnership will develop novel cancer biomarkers for oncology using the AutoGenomics INFINITI platform.
  • The first assay will be a gene expression assay associated with tumor response and resistance to compounds targeting the HER1 and HER2 pathways.
  • The HER1 and HER2 assay will provide valuable information to drug developers working with small molecule inhibitors or monoclonal antibody-based therapies.
  • Targeted Molecular Diagnostics will guide the development of BioFilmChip microarray content based on its expertise in targeted signaling pathways.
  • AutoGenomics will provide the technology to develop tests on its INFINITI System.
  • The partnership expects to release the first assay for clinical evaluation within 9 to 12 months.
  • Customized assays will be developed based on specific user requirements for clinical trials, drug, and disease studies.
  • The partnership's ultimate goal is to enable routine use of these biomarkers in clinical laboratories.

Statistics:

  • 3-year development partnership between AutoGenomics and Targeted Molecular Diagnostics.
  • Initial focus on the HER1 and HER2 pathways.
  • First assay to be released within 9 to 12 months.
  • Customized assays to be developed based on user requirements.

Sources:

  • AutoGenomics, Inc. and Targeted Molecular Diagnostics, Inc. Jointly Announce 3-Year Development Partnership in Cancer Biomarkers (Source: Science Letter, 2005)

Read more